Bardoxolone Blow-Up: Reata/Abbott CKD Drug Halted In Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Reata has terminated the Phase III BEACON trial for its chronic kidney disease hopeful bardoxolone methyl, partnered with Abbott, due to safety concerns.